特宝生物近期接受投资者调研时称,公司开展的Y型PEG化重组人生长激素注射液用于治疗儿童矮小症(特发性矮小症、小于胎龄儿、先天性卵巢发育不良综合征)项目,现在正处于临床研究阶段。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.